Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6390666rdf:typepubmed:Citationlld:pubmed
pubmed-article:6390666lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:6390666lifeskim:mentionsumls-concept:C0231335lld:lifeskim
pubmed-article:6390666lifeskim:mentionsumls-concept:C0002874lld:lifeskim
pubmed-article:6390666lifeskim:mentionsumls-concept:C0017710lld:lifeskim
pubmed-article:6390666lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:6390666lifeskim:mentionsumls-concept:C0444956lld:lifeskim
pubmed-article:6390666lifeskim:mentionsumls-concept:C0439661lld:lifeskim
pubmed-article:6390666pubmed:issue3lld:pubmed
pubmed-article:6390666pubmed:dateCreated1984-12-27lld:pubmed
pubmed-article:6390666pubmed:abstractText31 children with acute acquired aplastic anaemia were treated with very high doses of i.v. bolus methylprednisolone. In 3 of them, paroxysmal nocturnal haemoglobinuria was diagnosed. Therefore the responses of 28 patients have been evaluated. Normoblastaemia and reticulocytes were observed on about the 6th d and leucocyte and granulocyte response around the 11th d of treatment. The first haemoglobin (greater than or equal to 0.5 g/dl) and haematocrit elevations were documented on about the 16th d and the initial platelet response (average greater than or equal to 34 X 10(9)/l) took more than a month. At least 64% of the patients responded to this treatment including 2 cases in whom aplasia was observed following hepatitis. Although 10 episodes of recurrences occurred in 8 patients (with the exception of 3 patients' in whom 5 recurrences were observed), response to the same regimen was obtained. With 1 exception the side-effects of this treatment could be managed by decreasing the dose. With this treatment, acquired aplastic anaemia should no longer be considered a fatal disease, at least in children.lld:pubmed
pubmed-article:6390666pubmed:languageenglld:pubmed
pubmed-article:6390666pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6390666pubmed:citationSubsetIMlld:pubmed
pubmed-article:6390666pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6390666pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6390666pubmed:statusMEDLINElld:pubmed
pubmed-article:6390666pubmed:monthSeplld:pubmed
pubmed-article:6390666pubmed:issn0036-553Xlld:pubmed
pubmed-article:6390666pubmed:authorpubmed-author:OzsoyluSSlld:pubmed
pubmed-article:6390666pubmed:authorpubmed-author:Co?kunTTlld:pubmed
pubmed-article:6390666pubmed:authorpubmed-author:MinassaziSSlld:pubmed
pubmed-article:6390666pubmed:issnTypePrintlld:pubmed
pubmed-article:6390666pubmed:volume33lld:pubmed
pubmed-article:6390666pubmed:ownerNLMlld:pubmed
pubmed-article:6390666pubmed:authorsCompleteYlld:pubmed
pubmed-article:6390666pubmed:pagination309-16lld:pubmed
pubmed-article:6390666pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6390666pubmed:meshHeadingpubmed-meshheading:6390666-...lld:pubmed
pubmed-article:6390666pubmed:meshHeadingpubmed-meshheading:6390666-...lld:pubmed
pubmed-article:6390666pubmed:meshHeadingpubmed-meshheading:6390666-...lld:pubmed
pubmed-article:6390666pubmed:meshHeadingpubmed-meshheading:6390666-...lld:pubmed
pubmed-article:6390666pubmed:meshHeadingpubmed-meshheading:6390666-...lld:pubmed
pubmed-article:6390666pubmed:meshHeadingpubmed-meshheading:6390666-...lld:pubmed
pubmed-article:6390666pubmed:meshHeadingpubmed-meshheading:6390666-...lld:pubmed
pubmed-article:6390666pubmed:year1984lld:pubmed
pubmed-article:6390666pubmed:articleTitleHigh dose intravenous glucocorticoid in the treatment of childhood acquired aplastic anaemia.lld:pubmed
pubmed-article:6390666pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6390666lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6390666lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6390666lld:pubmed